It was recently found that CDK4/6 inhibitors (e.g., palbociclib), which are currently being tested clinically as a potential therapy for melanoma, can activate p53 through modulation of alternative splicing of MDM4, which is a known negative regulator of p53. The gene discussed is TP53; the disease is melanoma.